In a significant leap forward for heart failure therapy, the Texas Heart Institute (THI) teamed up with BiVACOR®, a company specializing in medical devices, to implant the first-of-its-kind total artificial heart in a patient suffering from severe biventricular heart failure. The procedure, which took place on July 9, was reported by The Houston Chronicle as a pivotal moment in a study sanctioned by the U.S. Food and Drug Administration aimed at providing a bridge to transplantation for those ineligible for left ventricular assist device support.
Dr. Joseph Rogers, President and CEO of The Texas Heart Institute, voiced excitement over the novel implantation. "We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population," he expressed in a statement obtained by The Houston Chronicle. Enrolled to follow in the clinical study, four other patients who are in dire need of a transplant will also receive this innovative treatment.
The BiVACOR Total Artificial Heart (TAH) represents a considerable advancement in artificial heart technology. As per details shared in a press release by Texas Heart Institute, the device is fashioned from titanium with a magnetically levitated rotor that substitutes both ventricles of a failing heart. This remarkable piece of engineering is said to be compact yet capable of providing sufficient cardiac output even during physical activity, fitting most men and women with a body surface area greater than 1.4 m2.
Dr. Rogers added, "With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant." Worldwide, heart failure affects over 26 million people, and with transplant opportunities being limited, this new device could potentially address the urgent needs of up to 100,000 patients immediately in the U.S., according to estimates by the U.S. National Institutes of Health, further highlighted by Daniel Timms, PhD, Founder and Chief Technology Officer of BiVACOR, in a statement obtained by the Texas Heart Institute. MAGLEV technology, which minimizes blood trauma by suspending the rotor without contact, thereby averting mechanical wear, is the innovation that makes the TAH's reliable and durable performance possible.
